Prostate Cancer Treatment and Research

Short Linear Motifs as a General Organizing Principle of the Nuclear-Receptor Proximal Interactome

The paper identifies two modes of nuclear receptor engagement through LXXLL motifs, showing how AR-V7 loses LXXLL-enriched interactions in cancer.

MZF1-mediated GAPDH overexpression drives glycolytic reprogramming and neuroendocrine progression in advanced prostate cancer

This study identifies MZF1-mediated GAPDH overexpression as a driver of glycolytic reprogramming and neuroendocrine progression in advanced prostate cancer, suggesting metabolic targeting as a therapeutic strategy.

The Establishment of Prostate-specific, SKP2 Humanized Mice by CRISPR Knock-in Method Reveals Neoplastic Initiation and Microenvironmental Reprogramming

This study establishes a prostate-specific hSKP2 knock-in mouse model to investigate SKP2's role in cancer initiation and microenvironmental changes.

INSM1 Regulates Neuroendocrine Plasticity and Tumor Progression in Prostate Cancer

This study identifies INSM1 as a key regulator of neuroendocrine plasticity and tumor progression in prostate cancer, showing its role in lineage programs and identifying HHT as a potential therapeutic agent.

Vitamin D deficiency alters prostate epithelial differentiation and increases prostate cancer aggressiveness in ex vivo and in vivo models

This study shows vitamin D deficiency impairs prostate epithelial differentiation and promotes cancer aggressiveness in both ex vivo and in vivo models.

IL-1β/IL-6 signaling circuit in the tumor microenvironment drives prostate cancer development

This study identifies an IL-1β/IL-6 signaling circuit in the tumor microenvironment that drives prostate cancer progression from pre-invasive to invasive stages.

An Integrated Preclinical Platform for Lethal Neuroendocrine Prostate Cancer from Rapid Autopsy Bone and Liver Metastases.

This paper establishes patient-derived models of neuroendocrine prostate cancer (NEPC) from metastases, showing they retain tumor heterogeneity and can model metastatic progression.

Coupled Cell-Intrinsic and Microenvironmental Heterogeneity Drives Divergent Trajectories in Castration-Resistant Prostate Cancer

This study develops a multiscale framework to analyze how cell-intrinsic and microenvironmental factors drive divergent trajectories in castration-resistant prostate cancer.

5β-Dihydrotestosterone reveals a mutant androgen receptor vulnerability in prostate cancer

This paper evaluates 5β-Dihydrotestosterone (5β-DHT) as a potential alternative to testosterone in bipolar androgen therapy (BAT) for prostate cancer, showing it activates AR signaling in mutant AR contexts and suppresses tumor growth with fewer side effects.

Interdependent androgen and glucocorticoid receptor signalling shapes prostate epithelial homeostasis

This study shows that glucocorticoid receptor (GR) interacts with androgen receptor (AR) to regulate prostate epithelial homeostasis through shared cis-regulatory elements.

A Glutamine antagonist-modulated tumor microenvironment unleashes enzalutamides immunotherapeutic effects

This study shows that combining enzalutamide with DRP-104 enhances anti-tumor immunity by reducing Treg cells and improving CD8+ T cell activity in prostate cancer.

Genotoxic antibody-drug conjugates combined with Bcl-xL inhibitors enhance therapeutic efficacy in metastatic castration-resistant prostate cancer

Genomic Determinants of Lethality and Therapeutic Vulnerability in Castration-Resistant Prostate Cancer

This study identifies genomic drivers of progression and therapeutic outcomes in mCRPC and develops a multi-omic classifier to predict patient survival across multiple therapies.

FOXI3 Promotes Migration and Proliferation in Prostate Cancer Bone Metastases, Modulated by FGF8.

Integrated multi-omics profiling uncovers the epigenetic, transcriptional, and metabolic landscape of prostate cancer progression

This study integrates DNA methylation, gene expression, and metabolic profiles to identify molecular pathways and signatures associated with aggressive prostate cancer and disease recurrence.

A Novel Drug Candidate that Selectively Targets the Critical Androgen Receptor-ELK1 Growth Axis in Advanced and Drug-Resistant Prostate Cancer

This paper develops a new compound KCI838 that selectively inhibits the AR-ELK1 axis in prostate cancer, showing potent anti-tumor activity in resistant models.

Binding of long non-coding RNAs within the androgen receptor N-terminal tail modulates interdomain communication and liquid-liquid phase separation

This study identifies the RNA-binding region of the androgen receptor and shows how lncRNA binding modulates interdomain communication and phase separation, contributing to ligand-independent AR signaling in prostate cancer.

SOCS1 expression in prostate epithelial cells is essential for tissue homeostasis and tumor suppression

This study shows that SOCS1 in prostate epithelial cells is crucial for tissue homeostasis and tumor suppression by controlling proliferation, inflammation, and DNA damage response.

Loss of PGC1α drives extracellular matrix remodelling in prostate cancer through CTHRC1

This study shows that loss of PGC1α in prostate cancer leads to ECM remodeling via CTHRC1, promoting tumor aggressiveness.

MYC pathway reprogramming through a TIP60 coactivator switch in neuroendocrine lineage transition in prostate cancer

The paper identifies a TIP60 coactivator switch in neuroendocrine prostate cancer, revealing a therapeutic target for MYC-driven diseases.

Dependencies in heterogeneous, lineage plastic patient-derived prostate cancer organoids revealed through integrated single-cell multiomics and CRISPR screening

The paper integrates single-cell multiomics and CRISPR screening in prostate cancer organoids to reveal lineage-specific dependencies and heterogeneity effects on gene essentiality.

Co-Targeting Nuclear Export and Translation Initiation Uncovers a Therapeutic Vulnerability in Lethal Prostate Cancer

This study identifies co-inhibition of XPO1 and EIF4A1 as a therapeutic strategy for mCRPC, showing synergistic antitumor effects at reduced drug doses.

Spatial single-cell proteomics defines multicellular niches in the primary prostate cancer microenvironment

The paper uses spatial single-cell proteomics to map multicellular niches in primary prostate cancer, identifying prognostic cell types and niches beyond Gleason grading.

Cell-resolved high-dimensional imaging analysis, therapeutic modeling, and a Phase Ib clinical study validate BCL-2 as a target across heterogeneous CRPC subtypes

This study validates BCL-2 as a therapeutic target in CRPC by showing its upregulation under AR inhibition and demonstrating efficacy of BCL-2 inhibitors in preclinical and clinical models.

HF-125, a first-in-class computer-modeled novel inhibitor of Tribbles 2, for therapy of enzalutamide resistant, neuroendocrine prostate cancer.

This paper designs HF-125, a TRIB2 inhibitor, using AI-based modeling to treat enzalutamide-resistant neuroendocrine prostate cancer.

Diabetes Might Shape Vasculature, Tumor Dissemination and Circulating Inflammation Marker Profiles in Prostate Cancer.

This study examines how type 2 diabetes affects prostate cancer progression, finding associations with advanced tumor stage, lymph node involvement, and altered tumor cell dissemination and vascular characteristics.

A forward genetic screen identifies Sirtuin1 as a driver of neuroendocrine prostate cancer

The paper uses a forward genetic screen in a mouse model to identify Sirtuin1 as a driver of neuroendocrine prostate cancer, showing its role in promoting NEPC and potential as a therapeutic target.

AR suppression rewires a SOX4 regulatory program to promote enzalutamide resistance in prostate cancer

The paper identifies a SOX4-driven regulatory program that promotes enzalutamide resistance in prostate cancer by rewiring gene regulation following AR suppression.

ECM (collagen) mediated signaling drives the emergence of androgen independence in prostate cancer cells

This study shows collagen in the tumor microenvironment promotes androgen independence in prostate cancer by enhancing cell migration, reducing chemotherapy sensitivity, and activating androgen receptor signaling through FAK.

A MYC Family Switch: L-MYC Drives and Maintains Neuroendocrine Lineage Programs in Prostate Cancer

This study identifies MYCL as a key driver of neuroendocrine lineage programs in prostate cancer by showing its upregulation in NEPC and its role in suppressing AR signaling and inducing neuroendocrine reprogramming.